{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T10:01:35Z","timestamp":1775728895177,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017346","name":"Nippon Boehringer Ingelheim Co. Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12325-026-03502-w","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:39:49Z","timestamp":1771580389000},"page":"1723-1740","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Tolerability of Nintedanib in Japanese Patients with Progressive Fibrosing Interstitial Lung Diseases: Final Results of 2-Year Post-Marketing Surveillance"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6456-2825","authenticated-orcid":false,"given":"Tomohiro","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"3502_CR1","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/jama.2024.3669","volume":"331","author":"TM Maher","year":"2024","unstructured":"Maher TM. Interstitial lung disease: a review. JAMA. 2024;331:1655\u201365.","journal-title":"JAMA"},{"key":"3502_CR2","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","volume":"383","author":"M Wijsenbeek","year":"2020","unstructured":"Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383:958\u201368.","journal-title":"N Engl J Med"},{"key":"3502_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","volume":"8","author":"AU Wells","year":"2020","unstructured":"Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8:453\u201360.","journal-title":"Lancet Respir Med"},{"key":"3502_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2017-000212","volume":"4","author":"KR Flaherty","year":"2017","unstructured":"Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res. 2017;4:e000212.","journal-title":"BMJ Open Respir Res"},{"key":"3502_CR5","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1007\/s12325-020-01384-0","volume":"37","author":"WA Wuyts","year":"2020","unstructured":"Wuyts WA, Papiris S, Manali E, et al. The burden of progressive fibrosing interstitial lung disease: a DELPHI approach. Adv Ther. 2020;37:3246\u201364.","journal-title":"Adv Ther"},{"key":"3502_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00085-2020","volume":"55","author":"KK Brown","year":"2020","unstructured":"Brown KK, Martinez FJ, Walsh SLF, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020;55:2000085.","journal-title":"Eur Respir J"},{"key":"3502_CR7","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0076-2018","volume":"27","author":"V Cottin","year":"2018","unstructured":"Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27:180076.","journal-title":"Eur Respir Rev"},{"key":"3502_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/resp.14245","volume":"27","author":"R Takei","year":"2022","unstructured":"Takei R, Brown KK, Yamano Y, et al. Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype. Respirology. 2022;27:333\u201340.","journal-title":"Respirology"},{"key":"3502_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01749-1","volume":"22","author":"M Nasser","year":"2021","unstructured":"Nasser M, Larrieu S, Boussel L, et al. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study). Respir Res. 2021;22:162.","journal-title":"Respir Res"},{"key":"3502_CR10","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"key":"3502_CR11","unstructured":"Nippon Boehringer Ingelheim Co. Ltd. Boehringer Ingelheim Japan receives approval for additional indication of OFEV\u00ae capsules for progressive fibrosing interstitial lung disease in Japan. https:\/\/www.boehringer-ingelheim.com\/jp\/press-release\/20200529-01.2020. Accessed July 10 2025."},{"key":"3502_CR12","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1007\/s12325-021-01786-8","volume":"38","author":"AL Olson","year":"2021","unstructured":"Olson AL, Patnaik P, Hartmann N, Bohn RL, Garry EM, Wallace L. Prevalence and incidence of chronic fibrosing interstitial lung diseases with a progressive phenotype in the United States estimated in a large claims database analysis. Adv Ther. 2021;38:4100\u201314.","journal-title":"Adv Ther"},{"key":"3502_CR13","unstructured":"Boehringer Ingelheim. FDA approves Ofev\u00ae as first treatment for chronic fibrosing ILDs with a progressive phenotype. https:\/\/www.boehringer-ingelheim.com\/us\/media\/press-releases\/fda-approves-ofev-first-treatment-chronic-fibrosing-ilds-progressive-phenotype.2020. Accessed July 10 2025"},{"key":"3502_CR14","unstructured":"Boehringer Ingelheim. European Commission approves third nintedanib indication in pulmonary fibrosis. https:\/\/www.boehringer-ingelheim.com\/human-health\/lung-diseases\/scleroderma\/europeancommissionapprovesnintedanibssc-ild. Accessed January 27 2026"},{"key":"3502_CR15","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718\u201327.","journal-title":"N Engl J Med"},{"key":"3502_CR16","unstructured":"Boehringer Ingelheim. FDA approves Ofev\u00ae as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD. https:\/\/www.boehringer-ingelheim.com\/us\/media\/press-releases\/fda-approves-ofev-first-and-only-therapy-slow-rate-decline-pulmonary-function-patients-systemic. Accessed January 27 2026"},{"key":"3502_CR17","unstructured":"Nippon Boehringer Ingelheim Co., Ltd. Ofev capsules: report on the deliberation results. https:\/\/www.pmda.go.jp\/files\/000243773.pdf.2020. Accessed August 19 2025."},{"key":"3502_CR18","doi-asserted-by":"publisher","first-page":"2004538","DOI":"10.1183\/13993003.04538-2020","volume":"59","author":"KR Flaherty","year":"2022","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J. 2022;59:2004538.","journal-title":"Eur Respir J"},{"key":"3502_CR19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00752-2023","volume":"63","author":"M Wijsenbeek","year":"2024","unstructured":"Wijsenbeek M, Swigris JJ, Inoue Y, et al. Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis. Eur Respir J. 2024;63:2300752.","journal-title":"Eur Respir J"},{"key":"3502_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-01974-2","volume":"23","author":"V Cottin","year":"2022","unstructured":"Cottin V, Martinez FJ, Jenkins RG, et al. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial. Respir Res. 2022;23:85.","journal-title":"Respir Res"},{"key":"3502_CR21","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382.","journal-title":"N Engl J Med"},{"key":"3502_CR22","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1136\/annrheumdis-2020-217331","volume":"79","author":"JR Seibold","year":"2020","unstructured":"Seibold JR, Maher TM, Highland KB, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. Ann Rheum Dis. 2020;79:1478\u201384.","journal-title":"Ann Rheum Dis"},{"key":"3502_CR23","first-page":"753","volume":"44","author":"T Ito","year":"2023","unstructured":"Ito T, Shibuya A, Saisho H. Safety and tolerability of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases. First interim report of a 2-year post-marketing surveillance. Ther Res. 2023;44:753\u201364.","journal-title":"Ther Res"},{"key":"3502_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106574","volume":"187","author":"Y Inoue","year":"2021","unstructured":"Inoue Y, Suda T, Kitamura H, et al. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. Respir Med. 2021;187:106574.","journal-title":"Respir Med"},{"key":"3502_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.resinv.2022.06.009","volume":"60","author":"T Ogura","year":"2022","unstructured":"Ogura T, Suda T, Inase N, et al. Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: further subset analysis from the whole INBUILD trial. Respir Investig. 2022;60:787\u201397.","journal-title":"Respir Investig"},{"key":"3502_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.resinv.2024.04.008","volume":"62","author":"Y Inoue","year":"2024","unstructured":"Inoue Y, Kitamura H, Okamoto M, et al. The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: a subset analysis of the INBUILD trial. Respir Investig. 2024;62:589\u201396.","journal-title":"Respir Investig"},{"key":"3502_CR27","unstructured":"Boehringer Ingelheim. Japanese risk management plan on Ofev\u00ae capsules 100 mg; Ofev\u00ae capsules 150 mg. Japanese. https:\/\/www.pmda.go.jp\/RMP\/www\/650168\/db1aa115-99c0-49dc-92c7-c16a61e91339\/650168_3999039M1022_022RMP.pdf. Accessed September 18 2025"},{"key":"3502_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211023357","volume":"9","author":"M Dobashi","year":"2021","unstructured":"Dobashi M, Tanaka H, Taima K, et al. The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: a multicenter retrospective study. SAGE Open Med. 2021;9:20503121211023357.","journal-title":"SAGE Open Med"},{"key":"3502_CR29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s12325-024-03079-2","volume":"42","author":"Y Inoue","year":"2025","unstructured":"Inoue Y, Ogura T, Azuma A, et al. Real-world safety, tolerability and effectiveness of nintedanib in patients with idiopathic pulmonary fibrosis: final report of post-marketing surveillance in Japan. Adv Ther. 2025;42:1075\u201393.","journal-title":"Adv Ther"},{"key":"3502_CR30","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1007\/s12325-022-02411-y","volume":"40","author":"T Ogura","year":"2023","unstructured":"Ogura T, Inoue Y, Azuma A, et al. Real-world safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: interim report of a post-marketing surveillance in Japan. Adv Ther. 2023;40:1474\u201393.","journal-title":"Adv Ther"},{"key":"3502_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11321-x","volume":"7","author":"S Ikeda","year":"2017","unstructured":"Ikeda S, Sekine A, Baba T, et al. Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis. Sci Rep. 2017;7:10811.","journal-title":"Sci Rep"},{"key":"3502_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-021-01598-0","volume":"21","author":"U Schmid","year":"2021","unstructured":"Schmid U, Weber B, Sarr C, Freiwald M. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. BMC Pulm Med. 2021;21:244.","journal-title":"BMC Pulm Med"},{"key":"3502_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.pupt.2017.11.004","volume":"48","author":"U Schmid","year":"2018","unstructured":"Schmid U, Doege C, Dallinger C, Freiwald M. Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2018;48:136\u201343.","journal-title":"Pulm Pharmacol Ther"},{"key":"3502_CR34","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0259-2024","volume":"21","author":"A Denis","year":"2025","unstructured":"Denis A, Tsiri P, Guiot J, Tzouvelekis A. A new era in the treatment of progressive fibrosing interstitial lung diseases. Breathe. 2025;21:240259.","journal-title":"Breathe"},{"key":"3502_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103900","volume":"24","author":"Y Kondoh","year":"2025","unstructured":"Kondoh Y, Fujii T, Inoue Y, Atsumi T. Unmet needs and emerging pharmacotherapies for autoimmune connective tissue disease-associated interstitial lung diseases. Autoimmun Rev. 2025;24:103900.","journal-title":"Autoimmun Rev"},{"key":"3502_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-024-00345-2","volume":"44","author":"Y Nishioka","year":"2024","unstructured":"Nishioka Y, Araya J, Tanaka Y, Kumanogoh A. Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease. Inflamm Regen. 2024;44:34.","journal-title":"Inflamm Regen"},{"key":"3502_CR37","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","volume":"392","author":"TM Maher","year":"2025","unstructured":"Maher TM, Assassi S, Azuma A, et al. Nerandomilast in patients with progressive pulmonary fibrosis. N Engl J Med. 2025;392:2203\u201314.","journal-title":"N Engl J Med"},{"key":"3502_CR38","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0206-2022","volume":"32","author":"M Kolb","year":"2023","unstructured":"Kolb M, Crestani B, Maher TM. Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. Eur Respir Rev. 2023;32:220206.","journal-title":"Eur Respir Rev"},{"key":"3502_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838449","volume":"13","author":"FE Herrmann","year":"2022","unstructured":"Herrmann FE, Hesslinger C, Wollin L, Nickolaus P. BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Front Pharmacol. 2022;13:838449.","journal-title":"Front Pharmacol"},{"key":"3502_CR40","doi-asserted-by":"crossref","unstructured":"Reininger D, Wolf F, Mayr CH, et al. Insights into the cellular and molecular mechanisms behind the antifibrotic effects of nerandomilast. Am J Respir Cell Mol Biol. 2025:Online ahead of print","DOI":"10.1165\/rcmb.2024-0614OC"},{"key":"3502_CR41","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.1111\/bph.17303","volume":"181","author":"D Reininger","year":"2024","unstructured":"Reininger D, Fundel-Clemens K, Mayr CH, et al. PDE4B inhibition by nerandomilast: effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells. Br J Pharmacol. 2024;181:4766\u201381.","journal-title":"Br J Pharmacol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03502-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03502-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03502-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:14:11Z","timestamp":1775726051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03502-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3502"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03502-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) as supported by Good Publication Practice (GPP) guidelines. Tomohiro Ito and Hiroko Noguchi are employees of Nippon Boehringer Ingelheim Co., Ltd. Akira Shibuya is an employee of EPS Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Ministry of Health, Labour and Welfare Good Post-Marketing Study Practice, and Good Vigilance Practice ordinances. Under these regulations, neither informed consent from patients nor ethics approval were required, as this was a non-interventional observational study using anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}